glutathione reductase diabetes Frontiers Glutathione System from Cyanobacteria to

Disclosures: Deeksha Kartik: Nothing to Disclose, Lara Murray: Nothing to Disclose, Jacqueline Brosnan-Cashman: PathAI: Employee, PathAI: Stock privately held company, Neel Patel: PathAI: Employee, Ylaine Gerardin: PathAI: Employee, Robert Egger: Nothing to Disclose, Adam Stanford-Moore: Nothing to Disclose 826 SIMPLE NONINVASIVE TESTS HAVE POOR DIAGNOSTIC ACCURACY FOR MASLD F2-3 IN A REAL WORLD CANADIAN COHORT Nashla Hamdan 1 Chinmay Bera 2 Heather Kosick 1 Keyur Patel 1 , 1 University of Toronto, 2 Toronto General Hospital Background: Several Non-invasive test (NIT) that have been proposed to identify patients with advanced fibrosis (F3-4) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

This can be particularly beneficial for individuals struggling with obesity or metabolic disorders

10.1016/j.bbrc.2019.04.108 101 WangY.ChenH.WeiX

Echinocandins inhibit the synthesis of the fungal cell wall component -(1,3)-D-glucan by targeting the -(1,3)-glucan synthase (216)